Alcoholic hepatitis (AH) continues to be a disease with high mortality and no efficacious medical treatment. Although severe AH is presented as acute on chronic liver failure, what underlies this transition from chronic alcoholic steatohepatitis (ASH) to AH is largely unknown. To address this question, unbiased RNA sequencing and proteomic analyses were performed on livers of the recently developed AH mouse model, which exhibits the shift to AH from chronic ASH upon weekly alcohol binge, and these results are compared to gene expression profiling data from AH patients. This crossanalysis has identified Casp11 (CASP4 in humans) as a commonly up-regulated gene known to be involved in the noncanonical inflammasome pathway. Immunoblotting confirms CASP11/4 activation in AH mice and patients, but not in chronic ASH mice and healthy human livers. Gasdermin-D (GSDMD), which induces pyroptosis (lytic cell death caused by bacterial infection) downstream of CASP11/4 activation, is also activated in AH livers in mice and patients. CASP11 deficiency reduces GSDMD activation, bacterial load in the liver, and severity of AH in the mouse model. Conversely, the deficiency of interleukin-18, the key antimicrobial cytokine, aggravates hepatic bacterial load, GSDMD activation, and AH. Furthermore, hepatocyte-specific expression of constitutively active GSDMD worsens hepatocellular lytic death and polymorphonuclear leukocyte inflammation. Conclusion: These results implicate pyroptosis induced by the CASP11/4-GSDMD pathway in the pathogenesis of AH.
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A lcohol hepatitis (AH) is a unique spectrum of alcoholic liver disease (ALD) with high short-term mortality as high as 50% and with limited efficacious medical treatments. (1) It is an acuteon-chronic liver disease characterized by hepatic steatosis (HS), ballooned hepatocytes with Mallory-Denk bodies, neutrophilic infiltration, and liver fibrosis (LF) or cirrhosis and clinically presented with decompensated liver functions with cholestasis, hypoalubuminemia, coagulopathy, and portal hypertension. (2) Patients with severe AH develop sepsis, liver failure, and multiorgan dysfunction, leading to rapid progression to death. Common treatments for AH include prednisolone and pentoxyfiline that are primarily aimed to suppress inflammation. But their outcome are still controversial, attributed to an inherent risk of increasing infection by the corticosteroid and to suppression of regenerative effects of tumor necrosis factor alpha by pentoxifyline. (3) Nutritional therapy to supplement calories and protein has been attempted, but its efficacy is variable among patients. Liver transplantation (LT) is successfully performed for AH patients, which improves short-and long-term survival, (4, 5) but requires the collective and coordinated efforts of hepatologists, surgeons, addiction specialists, and social workers, as well as the prolonged abstinence often required for transplantation in the United States, which is realistically difficult for patients with severe AH who are expected to have high short-term mortality.
Obviously, hepatocytes are the primary target of alcohol effects. Research during the past three decades has disclosed several key mechanisms of alcohol-mediated hepatocellular damage, including cytochrome P450 2E1-mediated oxidant stress, mitochondrial glutathione stress, endoplasmic reticulum stress, malondialdehydeacetaldehyde protein adducts, centrilobular hypoxia, suppressed autophagy, and lysosomal dysfunction, to list a few. (6) (7) (8) These mechanisms may likely coexist and synergistically promote cellular injury through sensitization of hepatocytes and priming of hepatocytes and other cell types, culminating in hepatocellular death characterized by apoptosis, necrosis, or necroptosis. However, these mechanistic events are primarily identified in animal models, which only produce fatty liver or mild steatohepatitis, and whether they are directly relevant to the pathogenesis of AH is unknown. This presents a major obstacle for the design of logical therapeutic modalities for AH. Another problem is the lack of information as to what chronic precursor lesions exist before the development of acute-on-chronic pathology in AH patients. This knowledge gap stems from our inability to access and study asymptomatic chronic alcoholic steatohepatitis (ASH) patients as recently addressed. (1, 9) Difficulties in reproducing the histology and clinical features of AH in animal models have undoubtedly been a major limiting factor for our progress in addressing these questions. However, recent developments of the mouse models with superimposing binge alcohol administration allowed reproduction of neutrophilic infiltration and aggravated liver pathology. (10) (11) (12) (13) In particular, we have developed a so-called hybrid feeding mouse model, which incorporated ad libitum feeding of the Western diet into the intragastric ethanol diet feeding which assures sustained high alcohol intake and intoxication. (12) This model develops chronic ASH (cASH) accompanied by macrophage activation and pericellular and perisinusoidal LF. Moreover, weekly binge in this model shifts inflammation to neutrophilic infiltration and induces ductular reaction, as observed in patients with AH, and some of the clinical features of AH such as splenomegaly, hypoalbuminemia, and increased plasma bilirubin levels. (12) This hybrid feeding model, with or without binge, thus provides a unique opportunity to investigate the mediators responsible for an acute-on-chronic phenotype of AH. To this end, we have applied a global unbiased RNA sequencing (RNA-seq) and proteomic analyses, and published gene profiling data from AH patient livers (14) versus normal livers were integrated to identify commonly regulated genes in the mouse model and AH patients. This pursuit identifies Casp11 (for mouse)/
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CASP4 (for human) as an up-regulated gene in both the mouse model and patients. CASP11 activation is evident in AH livers in both mice and patients and is accompanied by increased activation of Gasdermin-D (GSDMD), the recently discovered effector for pyroptosis, suicidal death of the cells infected with bacteria. Lossand gain-of-function manipulations for CASP11 and/or GSDMD confirm its importance in controlling bacterial infection and induction of AH in the model.
Materials and Methods

MICE AND CELLS
Male C57BL/6j, B6.129S4(D2)-Casp4t m1Yuan /J, B6.129P2-Il18 tm1Aki /J mice were subjected to the AH regimen as described. (12) It consists of 2 weeks of ad libitum feeding of chow or diet high in cholesterol and saturated fat (high-cholesterol/high-fat diet [HCFD]; #180529; Dyets Inc., Bethlehem, PA), surgical implantation of intragastric (iG) catheter, 1-week acclimatization with iG feeding of a control high-fat diet (corn oil, 36%Cal) for 60% of daily caloric requirement and ad libitum feeding of HCFD or chow for the remaining 40%Cal and switching to an ethanol high-fat diet with incrementally increasing ethanol concentration over an 8-week period for ethanol-fed mice. This hybrid feeding regimen produces cASH, and superimposition of weekly ethanol binge shifts liver pathology to AH. For AH mice, ethanol binge was given weekly from the second week by withdrawing ethanol infusion for 5-6 hours before and after the binge and administering an equivalent amount of ethanol withdrawn as a bolus (45 g/kg). For control mice, isocaloric dextrose was given as a bolus in the identical manner. Hepatocytes and hepatic macrophages were isolated by a standard collagenase perfusion and cultured 2 hours on a collagen-coated dish for extraction of proteins. Raw264.7 cells were electroporated with an increasing concentration of lipopolydsaccharide (LPS; 0.125-5.000 lg/mL) without or with Caspase-11/4 (CASP11/4) inhibitor (Santa Cruz Biotechnology, Dallas, TX) by Neon Transfection System (Invitrogen, Carlsbad, CA) and cultured 3-18 hours before protein extraction.
RNA EXTRACTION AND RT-qPCR
Total RNA was extracted from liver tissues by the Quick-RNA MiniPrep (Zymo Research, Irvine, CA) or Direct-zol RNA MiniPrep Kit (Zymo Research). For RT-qPCR, complementary DNAs (cDNAs) were synthesized from 1 lg of total RNA using the Maxima First Strand Synthesis Kit for RT-qPCR (Thermo Fisher Scientific, Waltham, MA). qPCR was performed by amplifying cDNA for 40 cycles using the SYBR Green PCR master mix (Applied Biosystems, Foster City, CA) and the ViiA 7 Real-Time PCR System (Applied Biosystems). Each threshold cycle (Ct) value was first normalized to the 36B4 (Rplp0) Ct value of a sample and subsequently to a control sample. Primers used are shown in Supporting Table S1 .
RNA-seq AND PROTEOMIC ANALYSIS
RNA samples were provided to the USC Genomics Core for library construction and sequencing. Library construction was carried out using the Illumina TruSeq RNA Sample Prep kit. Libraries were applied to an Illumina flow cell and run on the Illumina HiSeq 2000 as a single-end read for 50 cycles with total raw reads per sample averaged around 22 millions. RNA-seq data were analyzed with Partek Flow software (version 4; Partek Inc., St. Louis, MO). Raw sequencing reads were first trimmed from both ends with the Quality Score method and then mapped to the mouse genome mm10 using Tophat software (version 2.0.5) (15) with default parameter settings and using Gencode M2 annotation. (16) Read counts per gene/transcript in all samples were normalized using Upper Quartile normalization (17) and analyzed for differential expression by the Partek Gene Specific Analysis method. The differentially expressed gene (DEG) lists were generated for each comparison using the cutoff of false discovery rate <0.05 and fold changes greater than 2 either direction. Hierarchical clustering of samples based on DEG lists was carried out using Partek Genomic Suite (version 5). Downstream functional analysis of the DEG lists were carried out using Ingenuity Pathway System (Qiagen, Redwood City, CA). Hepatic gene expression profiling was also assessed in patients with AH (n 5 15) and normal livers (n 5 7) by DNA microarray as described. (14) All AH patients had transjugular liver biopsy and histological diagnosis of AH. They had the Maddrey's discriminant function of 59 1 6 and bilirubin of 12.5 1 1.21 mg/dL, with 77% defined as having severe AH based on Age-Bilirubin-INR-Creatinine score >6.71. (14) Proteomics sample preparation and mass spectrometry analysis was performed with an LTQ-Orbitrap-Velos mass spectrometer (Thermo Fisher Scientific) as described. (18) HEPATOLOGY, Vol. 67, No. 5, 2018 KHANOVA ET AL.
IMMUNOBLOTTING ANALYSIS, CASP4/11 ASSAY, AND CYTOKINE ENZYME-LINKED IMMUNOSOR-BENT ASSAY
Mouse liver proteins were extracted with radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology). AH patient and control human livers were obtained from the Clinical Resources for Alcoholic Hepatitis Investigators (1R24AA025017) of Johns Hopkins University (Baltimore, MD). These tissues were excised from explanted livers in patients with severe AH during LT, or wedge biopsies from the donor livers (normal control). Supporting Table S5 summarizes basic clinical information of 5 AH patients and 5 healthy donors. For GSDMD immunoblotting, the membrane and cytosolic proteins were isolated by using the Mem-PER Plus Membrane Protein Extraction kit (Thermo Fisher Scientific). Twenty40 lg of proteins were mixed with 63 sodium dodecyl sulfate (SDS) sample buffer, resolved by 6%-10% SDS/polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membrane, and immunoblotted. The sources and dilutions of primary antibodies used were: CASP1 (sc-514, 3500; Santa Crutz Biotechnology); CASP11/4 (M029-3, 3500; MBL International, Woburn, MA); interleukin-1b (IL-1b; #30311, 3500; R&D Systems, Minneapolis, MN); and GSDMD (G7422, 3500; Sigma-Aldrich, St. Louis, MO). CASP11/4 activity was determined in liver homogenate supernatant by a kit that uses the LEVD substrate cleavage motif (Abcam, Cambridge, UK). This assay has some cross-reactivity with CASP5, but not with CASP1-3 or 6-10. Interleukin (IL)-1 and IL-18 concentrations were determined in plasma or liver homogenate supernatant by enzyme-linked immunosorbent assay (ELISA; R&D Systems and MBL International).
HISTOLOGICAL ANALYSIS, MORPHOMETRIC ANALYSIS, AND PLASMA CHEMISTRY
Left, middle, and right liver lobes were sliced, fixed with 3% paraformaldehyde, and processed for paraffin embedding by Histology Core of the USC Research Center for Liver Diseases (P30DK048522) and hematoxylin and eosin (H&E) staining by the Morphology Core of the Southern California Research Center for ALPD and Cirrhosis for blind analysis. Histological grading was performed for macro-and microvesicular steatosis, liver necrosis, mononuclear cell (MNC) and polymorphonulear cell (PMN) inflammation, lipogranuloma, and fibrosis. In brief, 11, 21, 31, and 41 are assigned for micro-or macrovesicular steatosis based on <25%, 25%-49%, 50%-74%, and 75%-100% of cells with respective type of steatosis. MNC and PMN inflammation were graded as 11, 21, and 31 if each low-power view contains 1-2, 3-7, and more than 7 foci of infiltration, respectively, and 41 was assigned if every lobule contained several foci. PMNs infiltrated into the parenchyma were counted on stained liver sections of the three major lobes and expressed per 100 mm 2 . The numbers of hepatocytes undergoing lytic death versus surviving cells were counted over five views under 2003 magnification in three different lobes and expressed as the percent of dead hepatocytes. Immunostaining for ductular reaction/oval cells was performed using OV-6 antibody (sc-101863; Santa Cruz Biotechnology). Plasma chemistry, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and bile acids, was determined by ANTECH Diagnostics, Irvine, CA by using an autoanalyzer.
BACTERIAL DNA ISOLATION AND qPCR
A small portion of right liver lobe (150 mg) was aseptically removed for genomic DNA extraction. The qPCR was performed for 16S ribosomal RNA (rRNA) bacterial universal sequence and normalized to host 18S rRNA as performed. (19) 
ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION
Adeno-associated virus (AAV) serotype 8 was used to construct the vector that drives expression of active mouse GSDMD (amino acids [aa] 1-276) under the hepatocyte-specific transthyretin (Ttr) promoter (Vector Biolabs, Malvern, PA), and AAV-Ttr-eGFP (enhanced green fluorescent protein) was used as a control. Each mouse received 5 3 10e11 of genome copy of either AAV vector in 100 lL of phosphatebuffered saline by tail vein during the acclimatization period after the intragastric catheter implantation.
STATISTICAL ANALYSIS
All numerical data are expressed as the means and SEM, and the statistical significance of a difference between the two sets of data or among different groups was analyzed by Student t test or analysis of variance. 
Results
COMPARATIVE TRANSCRIPTOME ANALYSIS IN AH IN MICE AND PATIENTS
The hybrid feeding combining ad libitum consumption of the Western diet that is prevalent among AH patients and intragastric feeding of ethanol-containing diet, which assures high intake of ethanol as observed in human alcoholics, results in induction of cASH with macrophage infiltration and LF as shown. (12) Superimposing this regimen with weekly alcohol binge shifts liver pathology to alcoholic hepatitis with neutrophilic infiltration (herein abbreviated as AH) despite equal overall alcohol intake. (12) To identify mediators for the pathogenesis of AH, we have performed transcriptome analysis by RNA-seq and proteomic analysis on livers of cASH and AH mice and compared to control mice (control) with isocaloric hybrid feeding of chow and intragastric control liquid diet. These results were compared to liver microarray data on AH patient versus control subjects as reported. (10) Because the patient data do not have a group representing cASH, we first compared differentially regulated genes in AH patients versus control subjects with differentially regulated genes and proteins in AH mice versus control mice (Fig. 1C) . As shown in Venn diagrams, approximately 25% and 17% of up-regulated and down-regulated genes in mouse AH are also shared by patient AH data, respectively. Comparing RNA-seq and proteomic data from mice, only 7.8% and 7.3% of up-regulated and downregulated genes are included in the protein data, respectively (the lists shown in Supporting Tables S1 Chemokine signaling  CCR2, CD47, COL4A3, CXCL5, FCER1G, CAPG, ITGA6, ITGB2, MMP7, PLAU,  S100A4, SIRPA, SPP1, TGFBR1, TRPM4, COL4A3, ITGA6, TGFBR1, FGF21   19   Inflammasome activation  CASP11/4, FCER1G, ITGB2, ALCAM, GPX2, CCR2, CD47, LPL, ANXA4, SLPI,  IQGAP1, TRPM4, VTCN1, DYNLL1, RAP1GAP, CFTR, CAPG   17   Exosome formation  TSPAN8, CXCL5, CD53,ITGB2,ITGB6, FGF21,FGFR2, PLAU, S100A4, SPP1,  STMN1, TGFBR1, LTBP2, MSN, SERPINE2, FCER1G, PLAT, AKR1B10, VCAN,  SVEP1, GOLM1, TESC   22   Cell migration  ANXA3, CAPG, CCR2, CD47, CFTR, COL4A3, CXCL5, DDR1, EHF, F13A1,  FCER1G, FGFR2, IQGAP1, ITGA6, ITGB2, ITGB6, LAMC2, LTBP2, MMP7, MSN TGFBR1, THG1L, TOP2A, TRPM4, VCAN, VTCN1, WISP2   45   Metastasis  ALCAM, CAPG, CCR2, CD47, CXCL5, FGFR2, FRY, ITGA6, MMP7, PLAT, PLAU,  S100A4, SLC7A11, SPP1, TGFBR1, TOP2A, VTCN1   17   Cell necrosis  ALCAM, CASP4, CCR2, CD47, COL4A3, DYNLL1, EHF, F13A1, FCER1G, FGFR2,  FUBP1, GABRP, GPX2, ITGA6, ITGB2, LAIR1, MMP7, MSN, PCNA, PLAT, PLAU,  RAB32, RAP1GAP, S100A4, S100A6, SERPINE2, SIRPA, SLC7A11, SLPI, SOX4,  SPP1, ST14, STMN1, TGFBR1, TLR1, TOP2A, TRPM4, UBD, VCAN   39   Apoptosis  ALCAM, ANXA4, CASP4, CCR2, CD47, CD53, COL4A3, DDR1, DYNLL1, EHF,  F13A1, FCER1G, FGFR2, FUBP1, GABRP, GPX2, ITGA6, ITGB2, LAIR1, MLLT11,  MMP7, MSN, PCNA, PKHD1, PLAT, PLAU, RAB32, RAP1GAP, S100A4,  S100A6, SERPINE2, SIRPA, SLC7A11, SLPI, SOX4, SPINT1, SPP1, ST14,  STMN1, TGFBR1, THG1L, TLR1, TOP2A, TRPM4, and S2), whereas 37.5% and 68.2% of up-regulated and down-regulated proteins are also differentially regulated at the mRNA level. This is likely attributed to a number of factors, including the higher coverage obtained by RNA-seq analysis compared to proteomics analysis and well-appreciated posttranscriptional mechanisms, (20) which results in the low percentages of the former set of comparison, suggesting the low sensitivity of proteomic analysis which results in the low percentages of the former set of comparison. Differentially regulated genes in AH versus control in both the mouse model and patients were subjected to Ingenuity Pathway Analysis (IPA). This analysis identifies that genes implicated in cancer, cardiovascular disease, inflammation, organ injury, and immunologic disease are up-regulated in both the mouse model and patients in the manner suggestive of induced pathways for mitochondrial stress, cell death, inflammation, LF, and cell cycle/DNA damage, which are expected in AH (Fig. 1D) . Commonly down-regulated genes in AH mice and patients are functionally categorized into farnesoid X receptor (FXR), liver X receptor (LXR), constitutive androstane receptor (CAR), and pregnane X receptor (PXR) activation involved in bile acid, fatty acid, and xenobiotic metabolism (Fig. 1E) , suggesting impaired hepatocellular metabolic activities expected from failing livers in AH. These results represent transcriptome data-based confirmation of the important features of clinical AH reproduced by the mouse model.
Next, we asked what genes are differentially regulated in mouse AH versus cASH to identify potential driver genes for the transition from cASH to AH. This analysis shows 495 up-regulated and 465 downregulated genes in AH as compared to cASH, and 19.8% (98 genes) and 28.2% (131 genes) of these genes are also identified in the AH patient data compared to control subjects ( Fig. 1F ; Supporting Tables  S3 and S4 ). Again, the concordance rate for differentially regulated proteins in the mouse model is relatively poor for these commonly up-regulated genes in AH mice, likely attributed to the relatively lower coverage of the proteomic analysis. Ontology and pathway analysis of 98 commonly up-regulated genes reveal several functional categories for which many genes are induced, such as chemokine signaling, inflammasome activation, cell death, and fibrosis, which are expected from more pronounced inflammatory and fibrotic changes observed in AH (Table 1) . From these data, we are intrigued by two results: (1) Genes involved in the pathway activated by bacterial infection are up-regulated in both mice and patients, and (2) Casp11/4, which is involved in activation of noncanonical inflammasome and pyroptosis in response to bacterial infection, (21) is commonly upregulated in AH mice and humans. However, Casp1, which is involved in the canonical inflammasome pathway and shown to be activated in fatty livers of mice fed the Lieber-DeCarlie diet, (22) is not listed as an up-regulated gene. Casp11/4 up-regulation is of particular interest given that AH is associated with hepatic and systemic bacterial infection initiated by translocation of intestinal bacteria attributed to dysbiosis and leaky gut. (23, 24) NONCANONICAL CASP11-GSDMD PATHWAY, BUT NOT CANONICAL CASP1/IL-1b PATHWAY, IS ACTIVATED IN AH To confirm these transcriptome results on inflammasome caspases, we performed immunoblotting and qPCR analyses on livers from control, cASH, and AH mice. Neither pro-CASP1 nor p20 cleaved CASP1 proteins are induced in AH as compared to control ( Fig. 2A) . Expected from no CASP1 activation, no evidence of increased pro-IL-1b activation is detected in cASH or AH livers by immunoblotting analysis (Fig. 2B) . In fact, serum IL-1b levels tend to be lower in AH (Fig. 2C) , and liver IL-1b shows no difference in a group of mice subjected to the standard 8-week AH regimen (AH1) and tends to be reduced even in another group (AH2), which underwent an extended 12-week AH regimen (Fig. 2D) . In contrast, upregulation of pro-CASP11 and active CASP11 are evident in AH (Fig. 3A) . Casp11 mRNA is also upregulated in AH1 and AH2 (Fig. 3B) . Furthermore, caspase 11/4 activity in liver homogenate is also significantly increased in AH compared to control or cASH mice (Fig. 3C) . Serum IL-18 levels are increased in both AH1 and AH2 (Fig. 3C) . The noncanonical CASP11 activation activates GSDMD to cause pyroptosis. (25) Indeed, livers from AH mice, but not cASH or control mice, show an appearance of a 30-kD mature GSDMD (Fig. 3E) . To test GSDMD activation in a macrophage cell line, Raw264.7 cells were electroporated with an increasing concentration of LPS. With higher concentrations of LPS, mature GSDMD appears and pro-GSDMD is reduced, providing the evidence of GSDMD activation (Fig. 3F) . Furthermore, this activation was prevented by the CASP11 inhibitor (Santa Crutz Biotechnology), supporting that CASP11 is upstream of GSDMD activation (Fig. 3G) . To assess the cellular site of GSDMD activation, we isolated hepatocytes and hepatic macrophages from the AH model and their proteins were immunoblotted with anti-GSDMD antibody. Increased levels of pro-GSDMD were detected in both hepatic macrophages and hepatocytes from AH mice as compared to control mice, suggesting a priming effect (Fig. 3H) . A cleaved and mature form of GSDMD was also detected clearly in hepatic macrophages from AH and vaguely in hepatocytes (Fig. 3H ).
CASP11 DEFICIENCY PREVENTS GSDM ACTIVATION, HEPATOCYTE DEATH, AND LIVER BACTERIAL LOAD IN AH
To test the causal role of CASP11 in vivo, we used the mice that carry a knockout (KO) allele of Casp11 (B6N.129S4(D2)-Casp4 tm1Yuan IJ). This mouse is also defective in CASP1 and pro-IL-1b activation. However, because our results showed selective CASP11 activation, but not CASP1, in the AH model, this genetic approach was used to test the role of CASP11 in experimental AH. Casp11 KO mice were indeed defective in activation of GSDMD in the AH regimen whereas wild-type (WT) mice showed GSDMD activation (Fig. 4A) . Although no significant changes were noted in histological grading for steatosis and inflammation, the incidence of hepatocellular death was suppressed ( Fig. 4B and Supporting Fig. S2 ) and liver bacterial load, as assessed by PCR for the universal bacterial r16S, was reduced in Casp11 KO mice (Fig. 4C) . We confirmed decreased hepatocellular death by directly counting hepatocytes that had undergone typical lytic cell death or were still alive to determine the percentage of the death (1.87 6 0.34 in WT AH vs. 0.47 6 0.04% in Casp11 -/-AH; P < 0.01). Although serum ALT and AST levels were not affected, elevated levels of serum bile acids and alkaline phosphatase were significantly attenuated in Casp11 KO mice compared to WT mice (Fig. 4D-F) . Upregulated Il17 mRNA levels in liver of WT AH were markedly attenuated in Casp11 -/-AH mouse livers. Conversely, mRNA levels of IL-22, which antagonizes IL-17 expression and has hepatoprotective effects, (26) were increased in Casp11 -/-AH mice (Fig. 4G ).
IL-18 DEFICIENCY AGGRAVATES GSDMD ACTIVATION, HEPATOCYTE DEATH, LIVER BACTERIAL LOAD, AND SEVERITY OF AH
IL-18 was originally identified as an interferon-cinducing factor and is generally considered as a proinflammatory cytokine. (27) IL-18 deficiency or treatment with anti-IL-18 antiserum protects mice from acute endotoxemia. (28, 29) At the same time, IL-18 serves as one of the most important antimicrobial cytokines and facilitates the early antimicrobial response to Escherichia coli. (30) Because IL-18 is up-regulated in AH mice were counted and expressed as the percent of total hepatocytes as described in Materials and Methods. (E) Plasma AST, ALT, and alkaline phosphatase levels of the two groups of mice described above. (F) Immunoblotting analysis of cytosolic and membrane fractions of AH patient (A1-5) or healthy donor (C1-5) livers for CASP4 and GSDMD. As loading controls for cytosol and membrane proteins, GAPDH and JUP (junction plakoglobin) were immunoblotted, respectively. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (Fig. 3C ) concurrent with increased bacterial load (Fig.  4C) , we hypothesized that IL-18 deficiency may increase GSDMD activation attributed to increased bacterial infection. Indeed, in IL-18 KO (IL-18 -/-) mice, GSDMD activation and liver bacterial load were all significantly increased (Fig. 5A,C) . Concurrently, hepatocyte death and PMN infiltration were increased as assessed by both semiquantitative morphometry (Fig. 5B, above) and cell number counting (Fig. 5B,  below) . Intensified PMN infiltration was corroborated by higher hepatic Myeloperoxidase (Mpo) mRNA levels (Fig. 5D, left) . However, Cd68 mRNA expression, the marker for macrophages, was reduced in IL-18 KO mice (Fig. 5D, right) . Serum ALT, bile acids, and alkaline phosphatase levels were also increased significantly more than WT mice (Fig. 5E,F) . Hyalin body inclusion in perivenular hepatocytes were noted in IL-18 KO mice subjected to the AH regimen (arrows, Fig. 5G-a) . Additionally, ductular reaction, which is a prognostic indicator for worse AH, (31) was also intensified in IL-18 mice (Fig. 5G-b, H&E staining) and confirmed by OV-6 antibody staining (Fig. 5G-c,d ). Collectively, these results suggest that IL-18 deficiency increases liver bacterial load and GSDMD-mediated pyroptosis of hepatocytes, and worsens AH, the phenotype that is opposite of that observed with Casp11 KO mice.
HEPATOCYTE-SPECIFIC EXPRESSION OF MATURE GSDM
To directly test the causal role of the mature GSDMD in the model, we overexpressed a Nterminal (aa 1-276) active peptide of GSDMD versus eGFP as a control using an hepatotrophic AAV-8 serotype vector under the hepatocyte-specific promoter of Ttr. Mice were injected by tail vein with either vector before the commencement of intragastric ethanol diet feeding and sacrificed after 8 weeks of the AH regimen. Livers of mice injected with AAV-TtrmGSDMD showed a 4.8-fold increase in Gsdmd mRNA compared to those injected with AAV-TtreGFP (Fig. 5A ). Il18 and Casp11 mRNA were also increased 4-fold and 2-fold, respectively, in GSDMDoverexpressing livers compared to AH mice injected with the control virus. Histologically, liver pathology parameters such as macro-or microvesicular steatosis were not different between the two groups. However, hepatocyte death and PMN infiltration were significantly increased by GSDMD overexpression (Fig. 5B) . Hepatocyte death noted in AAV-Ttr-eGFP-treated mouse livers involved one to three cells surrounded by PMNs in each focus (arrows in Fig. 5C , left panel) whereas multiple hepatocytes exhibited lytic death with more intense PMN infiltration in AAV-TtrmGSDMD-injected mouse livers (demarcated by red lines in Fig. 5C, right panels) . The counting of dead hepatocytes revealed a more than 7% death rate in the AAV-Ttr-mGSDM group as opposed to 1.56 60.76% in the AAV-Ttr-eGFP group (Fig. 6D) . Plasma AST levels tended to be higher in GSDMDoverexpressing mice (P 5 0.07), resulting in a significant increase in AST/ALT ratio (1.43 60.09 vs. 1.0 60.05; P < 0.05).
CASP4-GSDMD ACTIVATION IN AH PATIENTS
Finally, we tested CASP4-GSDMD activation in livers from patients with severe AH and healthy donors obtained from the transplant program as described in Materials and Methods. Basic characteristics of 5 patients and their clinical information, as well as the age and sex of 5 healthy donors, are summarized in Supporting Table S5 . For these samples, membrane and cytosolic proteins were extracted to help detect active GSDMD in the membrane fraction by immunoblotting analysis. Explant livers from 5 patients with clinical and histological diagnosis of AH (A1-A5), all show a robust increase in cleaved, activated CASP4 in the cytosolic fraction and the appearance of 30 kD of mature GSDM in the membrane proteins, but not in healthy livers (C1-C5; Fig. 6F ), supporting the activated CASP4-GSDMD pathway in clinical AH.
Discussion
In search of putative drivers responsible for the transition from cASH to AH, we identified the noncanonical inflammasome caspase, CASP11/4, which is upregulated in both mouse and patient AH livers. CASP11/4 cleaves and activates GSDMD to induce programmed lytic cell death, called pyroptosis, in response to intracellular pathogens and pathogenassociated molecular patterns (PAMPs). (25, 32, 33) Thus, the CASP11/4-GSDMD pathway links bacterial translocation and infection with cellular death. In AH mice with an increased hepatic bacterial load, both CASP11 and GSDMD are activated, but not in cASH livers. CASP11 deficiency abrogates GSDMD activation, hepatocellular death, and liver bacterial load. Conversely, the deficiency of the antimicrobial, IL-18, aggravates these parameters and AH in mice. Furthermore, direct overexpression of the mature GSDMD in hepatocytes increases hepatocyte death and PMN infiltration in the AH model. Finally, the analysis of livers of patients with severe AH versus healthy controls confirms that the CASP4-GSDMD pathway is activated in clinical AH. Collectively, these results support the pivotal pathogenetic role of the CASP11/4-GSDMD pathway in AH and suggest that pyroptosis is a unique form of cell death in AH driven by translocated gut bacteria. Hepatocyes are sensitized or primed by ethanol or secondary factors to undergo apoptosis caused by activation of intrinsic or extrinsic proapoptotic pathways mediated by organelle stress or cytokines. (34) (35) (36) They may also undergo necroptosis mediated by receptor-interacting protein kinase (RIP) 1-RIP3 mixed-lineage kinase domainlike protein activation. (36, 37) Given that apoptosis may suppress necroptosis by caspase-mediated cleavage of RIP3 and the latter cell death is often associated with inflammatory response, apoptosis may occur in the early steatotic, but not inflammatory, stage of ALD followed by necroptosis in ASH. After the transition to AH, pyroptosis may dominate as a form of hepatocellular death mechanistically and consequentially associated with PMN inflammation and endotoxemia/ bacteremia (Fig. 7A) . Obviously, these different forms of hepatocellular death may coexist in ALD based on differences in individual cellular state of sensitization/ priming and bacterial infection, as well as heterogeneous microenvironment. (36) We also detected activated GSDMD in hepatic macrophages isolated from AH mouse livers. Given that hepatic macrophages are the first line of defense against translocated bacteria, this can be expected and also has a pathological significance. It may reduce the macrophage number and compromise local antimicrobial defense, further amplifying a vicious cycle of bacterial infection/pyroptosis/macrophage depletion. Indeed, liver expression of CD68, the marker for macrophages, is reduced in AH as compared to cASH (12) and further diminished in AH mice with IL-18 deficiency, always reciprocal to induction of Mpo, the marker for PMNs (Fig. 5D) . Pyroptosis of infected cells locally disseminates bacteria, PAMP, and deathassociated molecular pattern (DAMP), intensifying PMN infiltration into the hepatic macrophagesdepleted liver and worsening AH. With progressive pyroptosis and macrophage depletion, systemic dissemination of bacteria, PAMPS, and DAMPs may cause systemic inflammatory response syndrome (SIRS) and septicemia, the two common lifethreatening complications of AH (Fig. 7B) . The pro-GSDMD levels were increased in both hepatic macrophages and hepatocytes isolated from the AH model, suggesting the priming of this pyroptotic pathway. The mature form of GSDMD was detected in isolated hepatic macrophages, but not readily in hepatocytes. It was technically difficult to detect active GSDMD in hepatocytes, most likely because pyroptotic hepatocytes more easily underewent lysis during the isolation procedure. For this reason, we forced expression of GSDMD in hepatocytes through the AAV vector in the mouse model and demonstrated enhanced hepatocyte death with more intense PMN infiltration.
We noticed that plasma bile acids and alkaline phosphatase more sensitively responded to the manipulations of the CASP11-GSDMD pathway than plasma transaminases (Figs. 4 and 5) , suggesting that the ductal/ductular effect may be a primary event. In fact, CASP11 deficiency did not rescue HS and inflammation or plasma AST/ALT, but reduced these two parameters along with hepatocyte death and liver bacterial load. Indeed, the ductular reaction, which is known to correlate with the severity of clinical AH, (31) was clearly heightened when CASP11/4-GSDMD activation and liver bacterial load were worsened by IL-18 deficiency. Under such a condition, most liver parameters, including inflammation and ALT, were coordinately worsened. Endotoxin and inflammatory cytokines are known to induce cholestasis. (38, 39) We have previously reported that our AH model has enhanced activation of Toll-like receptor 4 (TLR4) signaling in close association with ductular reaction and up-regulation of progenitor genes such as Cd133 and Nanog. (12) A most recent study supports a role for the LPS-TLR4 pathway in ductular reaction in AH. (40) Collectively, these findings suggest that bacterial infection, which triggers the CASP11/4-GSDMD pyroptotic pathway in AH, may also target the bile duct epithelium to stimulate proliferation of ductular cells/oval cells.
It was surprising that despite the lack of CASP1-mediated canonical inflammasome activation, plasma IL-18 levels were increased in AH mice. This antimicrobial cytokine might have been processed and activated in extrahepatic sites. To this end, it is worth noting that human PMNs are shown to constitutively express IL-18 and IL-18-derived moieties through a mechanism mediated by caspase-independent cleavage of pro-IL-18 by the serine proteases, elastase and cathepsin G. (41) In fact, in an inflammatory environment, PMNs are a rich source of IL-18, which enhances PMN effector function, (42) establishing a functional pivotal positive loop. (41) In summary, the present study disclosed the unique role of the CASP11-GSDMD-pyroptosis pathway in mouse experimental AH and confirmed the activation of this pathway in clinical AH. Our results suggest that the components in this pathway may serve as therapeutic targets for AH.
